113 related articles for article (PubMed ID: 14681687)
21. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
Soldatenkov VA; Trofimova IN; Rouzaut A; McDermott F; Dritschilo A; Notario V
Oncogene; 2002 Apr; 21(18):2890-5. PubMed ID: 11973649
[TBL] [Abstract][Full Text] [Related]
22. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
24. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins.
Potikyan G; Savene RO; Gaulden JM; France KA; Zhou Z; Kleinerman ES; Lessnick SL; Denny CT
Cancer Res; 2007 Jul; 67(14):6675-84. PubMed ID: 17638877
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
26. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
27. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors.
Nishimori H; Sasaki Y; Yoshida K; Irifune H; Zembutsu H; Tanaka T; Aoyama T; Hosaka T; Kawaguchi S; Wada T; Hata J; Toguchida J; Nakamura Y; Tokino T
Oncogene; 2002 Nov; 21(54):8302-9. PubMed ID: 12447693
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
29. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
30. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?].
Foster DA; Gadir N
Ai Zheng; 2008 Aug; 27(8):882-4. PubMed ID: 18710627
[TBL] [Abstract][Full Text] [Related]
31. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
32. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation.
Deneen B; Denny CT
Oncogene; 2001 Oct; 20(46):6731-41. PubMed ID: 11709708
[TBL] [Abstract][Full Text] [Related]
33. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells.
Kim MS; Kim CJ; Jung HS; Seo MR; Juhnn YS; Shin HY; Ahn HS; Thiele CJ; Chi JG
J Pathol; 2004 Jan; 202(1):103-12. PubMed ID: 14694527
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin induces Smad activity in prostate cancer cell lines.
van der Poel HG; Hanrahan C; Zhong H; Simons JW
Urol Res; 2003 Feb; 30(6):380-6. PubMed ID: 12599018
[TBL] [Abstract][Full Text] [Related]
36. Establishment, characterization, and drug sensitivity of a new Ewing sarcoma cell line (SS-ES-1).
Rajabalian S; Hajializadeh Z; Pooraboli I; Jangi-Aghdam H; Badinloo M
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e331-7. PubMed ID: 20962673
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
[TBL] [Abstract][Full Text] [Related]
38. BLCAP induces apoptosis in human Ewing's sarcoma cells.
Fan DG; Zhao F; Ding Y; Wu MM; Fan QY; Shimizu K; Dohjima T; Nozawa S; Wakahara K; Ohno T; Guo YS; Ma BA; Jiang JL
Exp Biol Med (Maywood); 2011 Sep; 236(9):1030-5. PubMed ID: 21844121
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
40. Expression and regulation of the transcriptional repressor ZNF43 in Ewing sarcoma cells.
González-Lamuño D; Loukili N; García-Fuentes M; Thomson TM
Pediatr Pathol Mol Med; 2002; 21(6):531-40. PubMed ID: 12537770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
